Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.43 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 9/20 | 0.40 |
| ▸ | CDK8 | P49336 | 9/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2638708 | 0.88 | IDO1 (0.45) | CNR1CCNCCDK8SMN1; SMN2MEN1 | |
| SCHEMBL2635086 | 0.84 | OTUD7B (0.41) | CNR1OTUD7BMAPTSMN1; SMN2MEN1 | |
| SCHEMBL2637373 | 0.80 | IDO1 (0.49) | CNR1OTUD7BSMN1; SMN2ALDH1A1 | |
| SCHEMBL743165 | 0.78 | LIPE (0.48) | CCNCCDK8 | |
| SCHEMBL2637213 | 0.76 | IDO1 (0.46) | CNR1OTUD7BSMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL2637460 | 0.75 | IDO1 (0.47) | CNR1OTUD7BCCNCCDK8SMN1; SMN2 | |
| SCHEMBL2637275 | 0.75 | CNR1 (0.47) | CNR1OTUD7BCDK8SMN1; SMN2ALDH1A1 | |
| SCHEMBL2637344 | 0.75 | S100A9 (0.43) | CCNCCDK8SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2637421 | 0.75 | ALDH1A1 (0.50) | MEN1KMT2AALDH1A1NAMPT | |
| SCHEMBL4395824 | 0.74 | MAPT (0.69) | CNR1MAPTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116270-A1 | NOVEL COMPOUNDS | CONVERGENCE PHARMACEUTICALS LIMTED | 2013-05-09 | — | — | US | claimed |
| EP-2569318-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2013-03-20 | — | — | EP | claimed |
| WO-2011141729-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2011-11-17 | — | — | WO | claimed |
| US-20130116270-A1 | NOVEL COMPOUNDS | CONVERGENCE PHARMACEUTICALS LIMTED | 2013-05-09 | — | — | US | disclosed |
| US-20130116270-A1 | NOVEL COMPOUNDS | CONVERGENCE PHARMACEUTICALS LIMTED | 2013-05-09 | — | — | US | disclosed |
| US-20130116270-A1 | NOVEL COMPOUNDS | CONVERGENCE PHARMACEUTICALS LIMTED | 2013-05-09 | — | — | US | disclosed |
| EP-2569318-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011141729-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011141729-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116270-A1 | NOVEL COMPOUNDS | TRPV2, CACNA1C, CACNA1B | CNR1 194/4885OTUD7B 3372/4885CCNC 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.